A retrospective study evaluating the efficacy of combining Venetoclax with either azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia.

Trial Profile

A retrospective study evaluating the efficacy of combining Venetoclax with either azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 New trial record
    • 12 Dec 2017 Results (n=21) assessing efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top